Public trial registry of the CCC-Munich

Trial CC5013-MDS-005

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
CC5013-MDS-005
World
Full title
:

A Phase 3, multicenter, randomized, double-blind, placebo-controllerd, parallel-group study to compare the efficacy and safety of Lenalidomide (REVLIMID®) versus placebo in subjects with transfusion-dependent anemia due to IPSS low or intermediate- 1 Risk Myelodysplastic syndromes without deletion 5Q [31] and unresponsive or refractory to erythropoiesis-stimulating agents
im Hämalog

World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany Tum
Indications
Classification Code Description
- D46.9 Myelodysplastisches Syndrom, nicht näher bezeichnet
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Chemo

Participants
Function Prename Surname Organization
World Responsible contact Katharina Götze Keine Organisationseinheit angegeben Magnifier